Phase 1 study of neoadjuvant chemotherapy with capecitabine/bevacizumab for locally advanced lower rectal cancer.

Phase 1 study of neoadjuvant chemotherapy with capecitabine/bevacizumab for locally advanced lower rectal cancer. - Neoadjuvant CRT with capecitabine/bevacizumab for locally advanced lower rectal cancer.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005289

Enrollment

Registered

2011-03-22

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lower rectal cancer

Interventions

cepecitabine dose level o-2

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)histologically confirmed rectal adenocarcinoma 2)ECOG PS 0-1 3)T3 or T4 disease or tumors with perirectal nodal involvement

Exclusion criteria

Exclusion criteria: 1)distant organ metastasis 2)previous chemotherapy for colorectal cancer 3)previous radiotherapy for the pelvis 4)history of another malignancy witjin the last 5years

Design outcomes

Primary

Measure	Time frame
MTD, RD	—

Secondary

Measure	Time frame
pCR rate, response rate, R0 resection rate	—

Countries

Japan

Contacts

Public ContactKita

Osaka City University Hospital Department of ethics

ethics@med.osaka-cu.ac.jp06-6645-2121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026